Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

HCMBullishIndustry Newsnews

High materiality8/10

Hutchmed's Fanregratinib shows 42.5% ORR in FGFR2 ICC; China NDA priority review

Jun 24, 2026, 8:04 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong efficacy signals in a targeted ICC indication plus regulatory acceleration (NDA priority review) can drive near-term valuation upside, though single-arm data and early-stage validation introduce risk.

AI summary

What happened, with direct paths to the underlying reporting

HUTCHMED reported a registration-enabling Phase II signal for fanregratinib (HMPL-453) in FGFR2-fusion ICC with an IRC-assessed ORR of 42.5%, DCR of 83.9%, and median DoR of 6.9 months. China’s NMPA granted priority review for NDA in December 2025, adding near-term regulatory catalysts alongside an ESMO GI data presentation in July 2026. The company retains worldwide rights, suggesting meaningful upside if the China approval translates to commercialization and potential international expansion.

Phase II ORR 42.5% (CI 30.0–53.6) in FGFR2 ICC.
DoR 6.9 months; DCR 83.9% (CI 74.5–90.9).
PFS 6.9 months; OS 16.6 months reported.
NDA accepted in China with priority review (Dec 2025).
53 sites in China; all patients had ≥1 prior systemic therapy.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Hutchmed's Fanregratinib shows 42.5% ORR in FGFR2 ICC; China NDA priority review

Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026

Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength